Monte Rosa unveils first look at Novartis-backed molecular glue data

Phase 1 Results for MRT-6160

• MRT-6160 demonstrated deep VAV1 degradation of greater than 90% in the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study3

• The drug showed significant T and B cell functional inhibition3

• There was significant inhibition of cytokine release from T and B cells following ex-vivo stimulation3

• MRT-6160 exhibited a favorable safety and tolerability profile3

Implications and Next Steps

• The data supports advancing MRT-6160 to Phase 2 studies3

• Monte Rosa believes the results demonstrate broad potential applications in immune-mediated diseases3

• Novartis will be responsible for Phase 2 clinical development and commercialization going forward, as per their license agreement4

• Monte Rosa remains responsible for completing the ongoing Phase 1 study4

Background on the Collaboration

• In October 2024, Novartis and Monte Rosa entered a global license agreement for MRT-6160 and other VAV1-directed molecular glue degraders4

• Novartis paid $150 million upfront and Monte Rosa is eligible for up to $2.1 billion in milestone payments4

• The deal aims to accelerate clinical development of MRT-6160 across multiple indications4

This first clinical data readout appears to validate Monte Rosa's molecular glue degrader platform and the potential of MRT-6160 as a novel approach for treating autoimmune and inflammatory diseases. The results support progressing to later-stage trials under Novartis' leadership.

Sources:

3. https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-therapeutics-announces-fourth-quarter-2024-financial

4. https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-therapeutics-announces-global-license-agreement